Mean-difference plots by country: Countries with decreased variance and decreased mean height (95% confidence interval shaded). by Jewel Gausman (5210969)

PowerPoint Slides for: Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis by Bushinsky D.A. (3246690)

“…<b><i>Results:</i></b> Mean ± SE serum K decreased (maximum change per corresponding day, 0.6 ± 0.2 mEq/l, p = 0.009) and fecal K increased 58% on patiromer compared with the pretreatment week. …”

Density plots of normalised consumer final power (PC) for the six example networks, shown over decreasing ratios of mean consumer to mean resource potential, . by Natalie Davis (8556036)

“…<p>Each plot shows the density for the normalised consumer final power at = 0.75, 0.5, and 0.25, from left to right, as the ratio decreases due to increased resource flow during the simulation. …”

Mean-difference plots by country: Countries with decreased variance and no change in mean height (95% confidence interval shaded). by Jewel Gausman (5210969)

“…<p>Mean-difference plots by country: Countries with decreased variance and no change in mean height (95% confidence interval shaded).…”

Mean-difference plots by country: Countries with decreased variance and increased mean height (95% confidence interval shaded). by Jewel Gausman (5210969)

“…<p>Mean-difference plots by country: Countries with decreased variance and increased mean height (95% confidence interval shaded).…”

Mean-difference plots by country: Countries with increased variance and decreased mean height (95% confidence interval shaded). by Jewel Gausman (5210969)

“…<p>Mean-difference plots by country: Countries with increased variance and decreased mean height (95% confidence interval shaded).…”

Mean-difference plots by country: Countries with no change in variance and decreased mean height (95% confidence interval shaded). by Jewel Gausman (5210969)

“…<p>Mean-difference plots by country: Countries with no change in variance and decreased mean height (95% confidence interval shaded).…”

Baseline and end-point pain scores in the pregabalin and placebo groups, 2003–2020. by Emma T. L. Cheng (14486376)

Subjects:

Adjusted means and 95% confidence interval of blood pressure change from baseline to the follow-up in different general or abdominal obesity status change groups. by Yi-de Yang (6755798)

Subjects:

Mean change in incidence and diagnoses if testing rates decrease. by Richard T. Gray (282417)

Stable isotope biplots of end-members (colored points) faceted by coastscape and overlayed consumers (gray points). by Nathan D. McTigue (10706460)

Efficacy end points. by Youngmin Ko (3333819)

Subjects:

The ratio of standard deviation to mean dose (SD/mean) decreases with neuronal dose. by Murat Alp (781371)

Pitfalls of merging only considering end-points. by Almiqdad Elzein (13141038)

KCl pulse decreased membrane, but increased nuclear, detection of NHE1 in b.End3 endothelial cells. by Erika Liktor-Busa (3328125)

Mean daily consultation counts. by Yael Rachamin (6161423)

The density of PNN in HVC is no longer decreased 4 months after treatment with ChABC. by Gilles Cornez (718394)

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Treatment effect of pregabalin over publication year* by dose. by Emma T. L. Cheng (14486376)

Subjects:

Triclabendazole decreases intracellular cAMP. by Yong Joo Lee (357685)